Navigation Links
TGen Drug Development establishes European footprint
Date:11/19/2009

SCOTTSDALE, Ariz. Nov. 18, 2009 TGen Drug Development (TD2) and the Institut Paoli-Calmettes (IPC) have forged a strategic alliance that will enable both to maximize their worldwide contributions in the treatment of cancer patients.

The partnership between TD2, a Scottsdale subsidiary of the Phoenix-based Translational Genomics Research Institute (TGen), and Marseille, France-based IPC's comprehensive cancer center will enable both non-profit institutes to speed research discoveries to patients with cancer.

Both organizations will expand their clinical research network to evaluate new therapies in the U.S. and Europe in an effort to more quickly introduce new drugs into clinical trials.

Teams from both TD2 and IPC will focus their efforts on discovering molecular alterations within cancers and finding biomarkers that will help identify new therapeutic targets that can be used to tailor treatments for individual patients.

IPC and TD2 will collaborate on a number of primary tumor and metastasis in selected cancers, as well as initiate an exchange program for medical oncologists between the two institutions.

"Aligning with IPC represents a significant opportunity for TD2 and TGen to further expand our research affiliations into Europe," said Dr. Daniel Von Hoff, TGen's Physician-In-Chief. "In addition to our ongoing collaborations with Luxembourg, this new alliance with IPC will further our goals across both Europe and the United States of providing better treatments in a more timely fashion to our many patients who suffer from a variety of cancer types."

Professor Patrice Viens, a medical oncologist and General Director of IPC, said the alliance with TD2 will enable IPC to bridge new international relationships: "This alliance with TD2 translates to our continuing efforts to expand our collaborations in basic research and medical activities beyond Europe.''

IPC is one of the largest university-affiliated comprehensive cancer centers in France, involved in the management of nearly 6,000 new cases of cancer each year. IPC established a Biological Resource Center (BRC) in oncology that has 70,000 tumor and biological fluid samples, mostly of breast, pancreatic and blood cancers. ICP had more than 600 patients in clinical trials during 2008.

IPC is affiliated with the Ovarian Cancer Diagnosis Initiative (OVCAD), which is dedicated to ovarian cancer research, and with the European Consortium for Anticancer Antibody Development (EUCAAD), a European consortium dedicated to anti-angiogenic treatments. It also is involved in collaborations with biotech and pharmaceutical companies.

IPC will join TGen's Pancreatic Cancer Research Team (PCRT), which includes other U.S. and international researchers.

"Our meetings at TGen have confirmed our decision to team up with this premier organization on the cutting edge of research and pharmacogenomics in oncology," Professor Viens said. "In addition we are thrilled to work again with Dr. Von Hoff." Professor Viens and Dr. Von Hoff once worked together at the University of Texas Health Science Center in San Antonio, Texas.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. Gender, coupled with diabetes, affects vascular disease development
2. New target for anti-flu drug development
3. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
4. KAUST and American University in Cairo to collaborate on research and academic development
5. Old developmental pathways spawn revolutionary evolutionary changes
6. NIST announces 56 new awards for innovative technology research and development
7. Progress Against Malaria: Developments on the Horizon
8. Flu vaccine in painless skin patches under development at Emory, Georgia Tech with NIH grants
9. Biopharmaceutical infrastructure key to lower drug development costs
10. Study identifies pathway required for normal reproductive development
11. 200 journals join in theme issues on poverty and human development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology: